+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

B-Cell Non-Hodgkins Lymphoma Market Size and Trend Report including Epidemiology, Disease Management, Pipeline Analysis, Competitor Assessment, Unmet Needs, Clinical Trial Strategies and Forecast, 2021-2031

  • PDF Icon

    Drug Pipelines

  • 36 Pages
  • December 2022
  • Region: Global
  • GlobalData
  • ID: 5720165
This report includes an assessment of the disease epidemiology and 10-year patient-based forecast (PBF) across the eight major pharmaceutical markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China) for marketed and pipeline therapies with established mechanisms of action by class, including early to late clinical stage pipeline products, with a launch date assessment by market for B-cell non-Hodgkin's lymphoma (NHL). This report also contains sales forecast extrapolations for an additional seven geographical markets (7M), totaling 15 markets (15M). These sales forecast extrapolations leverage data on pharmaceutical sales and drug availability from the publisher's World Markets Healthcare (WMH) and PharmOnline International (POLI) Price Intelligence databases.

The report also analyzes the clinical and commercial landscapes of B-cell NHL, with pricing assumptions based on currently marketed products by class of cell therapies, accompanied by a transparent forecast methodology. Additionally, the report evaluates indication-specific unmet needs and competitive assessments, and identifies key future players in the B-cell NHL therapy market.


  • Cell therapies face a high level of competition in NHL. The first line of therapy is well served by combination therapies, particularly chemotherapy plus Rituxan/biosimilar rituximab, which induces durable remissions in a large subset of patients.
  • The B-cell NHL pipeline is dominated by CAR-T cells. The success of CAR-Ts in NHL has fueled R&D investment into this class of therapy, with more CAR-Ts in development than all other cell and gene therapy (CGT) classes combined. Pipeline CAR-Ts will likely require a novel target, increased efficacy, lower price, or simplified manufacture to penetrate the crowded CAR-T market.
  • The NHL CGT market is projected to reach $8.4 billion in 8MM peak sales.
  • A high level of unmet need exists in certain patient populations, and could be addressed by CGT agents.

Key Highlights

  • Report deliverables include a PowerPoint report and Excel-based forecast model
  • Forecast includes 8 countries
  • Forecast covers 2021-2031
  • Seven markets are extrapolated, obtaining a 15-market value for all NHL therapeutics


  • This report includes disease epidemiology, a 10-year patient-based forecast for marketed and pipeline therapies with established mechanisms of action and cell therapies by class, including early- to late clinical stage pipeline products with launch date assessment by 8MM market.

Reasons to Buy


Our indication specific forecast models answer questions such as:

  • What is the target patient pool for cell & gene therapies in each cancer indication?
  • Which patient groups are more likely to receive these therapies?
  • What does the cell & gene therapy clinical stage pipeline look like in each cancer indication
  • What is the anticipated breakdown between autologous and allogeneic cell therapies?
  • When will cell & gene therapies launch in eac h market?
  • What is the total market value projected for the forecast end, in 2031?

Table of Contents

1. Preface
1.1. Contents
1.2. Report Scope

2. Executive Summary

3. Disease Overview
3.1. Etiology & Epidemiology
3.2. B-Cell NHL Treatment Algorithm

4. Pipeline Drugs Overview
4.1. Pipeline Analysis
4.2. Target Analysis and Clinical Benchmarks

5. Market Outlook
5.1. 10-Year Market Analysis with Drivers and Barriers

6. Unmet Needs

7. Likelihood of Approval Analysis and Phase Transition Success Rate Analysis

8. Competitive Assessment
8.1. Competitive Analysis by Class of Therapy

9. Future Players
9.1. Future Players Based on Pipeline Strength

10. Appendix
10.1. Cell Therapies Forecast Methodology Overview
10.2. Pricing of Cell Therapies
10.3. Pipeline Launch Assumptions
10.4. Abbreviations
10.5. Methodology
10.6. About the Authors

11. Contact the Publisher

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Bristol-Myers Squibb
  • Gilead
  • JW Therapeutics
  • Merck & Co
  • Novartis
  • Allogene Therapeutics
  • Caribou Biosciences
  • Fate Therapeutics
  • 2SEventyBio